Literature DB >> 10186464

Methodological quality of economic modelling studies. A case study with hepatitis B vaccines.

T Jefferson1, V Demicheli.   

Abstract

The notable increase in the quantity of economic evaluations in the last 2 decades has not been matched by good methodological standards. This problem is particularly evident in the field of economic evaluations of hepatitis B vaccines. The results of 2 systematic reviews conducted by us in 1993 and 1996 showed three problem areas. A sizeable minority of study reports failed to provide a clear study aim, showing a basic ignorance of the first rule of conducting scientific research. The basic epidemiological assumptions upon which the economic models were based showed variability which persisted even after stratification, raising the question of the accuracy of the epidemiological knowledge base of hepatitis B infection and its progression. Lastly, many of the studies showed weaknesses in basic methods of conducting and reporting economic evaluations. Examination of these problem areas led us to conclude that no conclusions about the efficiency of hepatitis B vaccines could be drawn from the available evidence. Addressing the problem of poor methodological standards concerns the whole research community. However, as a proportion of economic evaluations are published, one obvious means of exerting pressure to increase and maintain methodological standards is the editorial and peer review process. Editors of specialist and general medical journals should agree on and enforce common explicit guidelines for study conduct and reporting, following the example of the British Medical Journal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10186464     DOI: 10.2165/00019053-199814030-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  25 in total

1.  Cost-benefit analysis of the introduction of mass vaccination against hepatitis B in Italy.

Authors:  V Demicheli; T O Jefferson
Journal:  J Public Health Med       Date:  1992-12

2.  [A cost-effectiveness analysis of vaccination against the hepatitis B virus].

Authors:  F Antoñanzas; T Forcén; R Garuz
Journal:  Med Clin (Barc)       Date:  1992-06-06       Impact factor: 1.725

3.  The cost-benefit approach.

Authors:  A Williams
Journal:  Br Med Bull       Date:  1974-09       Impact factor: 4.291

4.  The public's health unprotected. Reversing a decade of underutilization of hepatitis B vaccine.

Authors:  D P Francis
Journal:  JAMA       Date:  1995-10-18       Impact factor: 56.272

5.  Are guidelines for peer-reviewing economic evaluations necessary? A survey of current editorial practice.

Authors:  T Jefferson; V Demicheli
Journal:  Health Econ       Date:  1995 Sep-Oct       Impact factor: 3.046

Review 6.  Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board.

Authors:  P Van Damme; M Kane; A Meheus
Journal:  BMJ       Date:  1997-04-05

7.  The quest for trials on the efficacy of human vaccines. Results of the handsearch of Vaccine.

Authors:  T Jefferson; V Jefferson
Journal:  Vaccine       Date:  1996-04       Impact factor: 3.641

8.  Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; S Berger; D Shouval
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

9.  A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.

Authors:  B S Bloom; A L Hillman; A M Fendrick; J S Schwartz
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

10.  Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.

Authors:  H S Margolis; P J Coleman; R E Brown; E E Mast; S H Sheingold; J A Arevalo
Journal:  JAMA       Date:  1995-10-18       Impact factor: 56.272

View more
  1 in total

Review 1.  Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.